AKRO:NSD-Akero Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 9.30

Change

-0.09 (-0.96)%

Market Cap

USD 0.33B

Volume

0.31M

Avg Analyst Target

USD 29.00 (+211.83%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Akero Therapeutics Inc (AKRO) Stock Analysis:
Based on the Akero Therapeutics Inc stock forecasts from 0 analysts, the average analyst target price for Akero Therapeutics Inc is USD 29.00 over the next 12 months. Akero Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Akero Therapeutics Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Akero Therapeutics Inc’s stock price was USD 9.30. Akero Therapeutics Inc’s stock price has changed by -7.37% over the past week, -24.57% over the past month and -67.03% over the last year.

About

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+9.49 (+1.47%)

USD70.91B 8.97 6.88
VRTX Vertex Pharmaceuticals Incorpo..

+7.45 (+3.02%)

USD63.10B 27.38 17.74
MRNA Moderna Inc

-1.65 (-1.20%)

USD54.86B 4.87 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

-7.64 (-4.81%)

USD38.60B 3.81 1.75
RPRX Royalty Pharma plc

+0.32 (+0.80%)

USD26.93B 26.81 14.86
SGEN Seagen Inc

+6.91 (+5.09%)

USD24.97B 55.02 44.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
GMAB Genmab A/S

+0.06 (+0.20%)

USD19.19B 46.16 5.06
ARGX argenx SE

-2.74 (-0.88%)

USD16.75B N/A N/A

ETFs Containing AKRO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -56.03% 33% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.03% 33% F 19% F
Trailing 12 Months  
Capital Gain -66.55% 46% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.55% 46% F 21% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.32% 49% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.32% 49% F 46% F
Risk Return Profile  
Volatility (Standard Deviation) 34.50% 80% B- 46% F
Risk Adjusted Return 9.62% 51% F 40% F
Market Capitalization 0.33B 67% D+ 50% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.18 47% F 75% C
Price/Book Ratio 2.15 40% F 38% F
Price / Cash Flow Ratio -4.13 63% D 69% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -47.11% 59% F 24% F
Return on Invested Capital -47.16% 57% F 21% F
Return on Assets -26.90% 48% F 15% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 19.41 5% F 2% F
Short Percent 15.97% 9% F 10% F
Beta 0.54 83% B 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.